

JAN 04 2008

Appn. Number 10/811,413 (Sung et al.) GAU 1615 Amnt. B contd. Page 3 of 5

AMENDMENTS TO THE CLAIMS:

Please cancel claims 1-4, 6-17, and 19-20. Please amend claims 22-30.

A complete listing of all claims and their current status is presented below.

1-4.(cancelled)

5.(previously presented) A biodegradable stent for treating vulnerable plaques or atherosclerotic plaques of a patient comprising:

at least two zones, wherein a first supporting zone comprises a first biodegradable material;

a second therapeutic zone comprising a second biodegradable material, wherein at least one of the first and the second biodegradable material further comprises a biological material, wherein said biological material is crosslinked with a crosslinking agent or with ultraviolet irradiation; and

wherein the crosslinking agent is genipin, its analog, derivatives, and combination thereof.

6-17.(cancelled)

18.(previously presented) A biodegradable stent for treating vulnerable plaques or atherosclerotic plaques of a patient comprising:

at least two zones, wherein a first supporting zone comprises a first biodegradable material;

a second therapeutic zone comprising a second biodegradable material, wherein at least one of the first and the second biodegradable material comprises at least one bioactive agent and wherein the at least one bioactive agent comprises lipostabil.

19-20.(cancelled)

21.(previously presented) The stent according to claim 5, wherein said biological material is selected from the group consisting of collagen, gelatin, elastin, chitosan, N, O, carboxymethyl chitosan, and mixture thereof.

22.(currently amended) To The stent according to claim 5, wherein at least one of the first and the second biodegradable material is a shape memory polymer.

Appn. Number 10/811,413 (Sung et al.) GAU 1615 Amnt. B contd. Page 4 of 5

23.(currently amended) ~~To~~ The stent according to claim 5, wherein at least one of the first and the second biodegradable material comprises at least one bioactive agent.

24.(currently amended) ~~To~~ The stent according to claim 5, wherein at least one of the first and the second biodegradable material comprises at least one bioactive agent and wherein the at least one bioactive agent comprises lipostabil.

25.(currently amended) ~~To~~ The stent according to claim 5, wherein at least one of the first and the second biodegradable material comprises at least one bioactive agent and wherein the at least one bioactive agent comprises analgesics/antipyretics.

26.(currently amended) ~~To~~ The stent according to claim 5, wherein at least one of the first and the second biodegradable material comprises at least one bioactive agent and wherein the at least one bioactive agent comprises ApoA-I Milano or recombinant ApoA-I Milano/phospholipid complexes.

27.(currently amended) ~~To~~ The stent according to claim 5, wherein at least one of the first and the second biodegradable material comprises at least one bioactive agent and wherein the at least one bioactive agent comprises a growth factor.

28.(currently amended) ~~To~~ The stent according to claim 5, wherein at least one of the first and the second biodegradable material comprises at least one bioactive agent and wherein the at least one bioactive agent comprises everolimus.

29.(currently amended) ~~To~~ The stent according to claim 5, wherein at least one of the first and the second biodegradable material comprises at least one bioactive agent and wherein the at least one bioactive agent comprises angiotensin converting enzyme inhibitors.

30.(currently amended) ~~To~~ The stent according to claim 5, wherein at least one of the first and the second biodegradable material comprises at least one bioactive agent and wherein the at least one bioactive agent comprises endothelial progenitor cells.